Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment. (Q40707724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Sabine Steiner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Helmut Sinzinger

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

23 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

published in

Vienna Clinical Weekly

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

655-663

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

15-16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201613%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00508-015-0833-4

20 February 2020

exact match

0 references

cites work

Familial hypercholesterolemia and coronary heart disease: a HuGE association review

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Lipid apheresis, indications, and principles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Current perspectives on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

A systematic review and economic evaluation of statins for the prevention of coronary events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Recommendations for the use of LDL apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

The 2009 2nd Italian Consensus Conference on LDL-apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Differential indication of lipoprotein apheresis during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Lipidfiltration--safe and effective methodology to perform lipid-apheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Efficacy criteria and cholesterol targets for LDL apheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Retrospective analysis of long-term lipid apheresis at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Lipoprotein apheresis in isolated hyperlipoproteinemia(a): a validated treatment or an illusion of validity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Plasma exchange in the management of homozygous familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Anticoagulation techniques in apheresis: from heparin to citrate and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Safety and effectiveness of long-term LDL-apheresis in patients at high risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Low-density lipoprotein apheresis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Contact activation in low-density lipoprotein apheresis systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00508-015-0833-4

Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis

21 January 2018

1 reference

12 December 2020

Homozygous familial hypercholesterolemia among French Canadians in Québec Province

1 reference

12 December 2020

Guidelines for the management of familial hypercholesterolemia

1 reference

12 December 2020

Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group

1 reference

12 December 2020

Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).

1 reference

12 December 2020

Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group

1 reference

12 December 2020

LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2alpha

1 reference

12 December 2020

Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis

1 reference

12 December 2020

Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia

1 reference

12 December 2020

Efficacy and safety measures for low density lipoprotein apheresis treatment using dextran sulfate cellulose columns

1 reference

12 December 2020

The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels

1 reference

12 December 2020

LDL-Apheresis removes serum amyloid P and A in hypercholesterolemic patients

1 reference

12 December 2020

Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia

1 reference

12 December 2020

Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment

1 reference

12 December 2020

Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies

1 reference

12 December 2020

Angiotensin receptor antagonists during dextran sulfate LDL-apheresis are safe

1 reference

12 December 2020

Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia

1 reference

12 December 2020

Ex-vivo and in-vivo platelet function in patients with severe hypercholesterolemia undergoing LDL-apheresis

1 reference

12 December 2020

Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study

1 reference

12 December 2020

Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan

1 reference

12 December 2020

Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-

1 reference

12 December 2020

Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations

1 reference

12 December 2020

Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia

1 reference

12 December 2020

Effect of lipoprotein apheresis on oxidative stress and antioxidant status in familial hypercholesterolemic patients

1 reference

12 December 2020

LDL-apheresis and concomitant ACE-inhibitor therapy

1 reference

12 December 2020

Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood

1 reference

12 December 2020